Genmab A/S and Cytokine PharmaSciences, Inc. announced that Genmab has licensed rights to the MIF receptor target from Cytokine PharmaSciences. Genmab intends to develop therapeutic human antibodies to the licensed target. Details of the agreement were not disclosed.

"We are enthusiastic about this target, especially as there has been positive proof of concept data in experimental animal models," said Lisa N. Drakeman, Ph.D., chief executive officer of Genmab.

Denny Willson, president and CEO of Cytokine PharmaSciences, stated: "Genmab is a world-class company in the area of developing human antibody therapeutics. We are pleased to entrust our target to an organization of their caliber."

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products.

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company licenses technologies from academia and other sources, develops products from those technologies and outlicenses the products to third parties for marketing.